The
epidermal growth factor receptor (EGFR) tyrosine kinase is
implicated in a large number of human cancers. Most EGFR inhibitors
target the extracellular, growth factor-binding domain or the intracellular,
ATP-binding domain. Here we describe molecules that inhibit the kinase
activity of EGFR in a new way, by competing with formation of an essential
intradimer coiled coil containing the juxtamembrane segment from each
member of the receptor partnership. The most potent molecules we describe
bind EGFR directly, decrease the proliferation of wild-type and mutant
EGFR-dependent cells lines, inhibit phosphorylation of EGFR and downstream
targets, and block coiled coil formation as judged by bipartite tetracysteine
display. Potency is directly correlated with the ability to block
coiled coil formation within full-length EGFR in cells.
Previous work has shown that certain β3-peptides can effectively mimic the side chain display of an α-helix and inhibit interactions between proteins, both in vitro and in cultured cells. Here we describe a β3-peptide analog of GLP-1, CC-3Act, that interacts with the GLP-1R extracellular domain (nGLP-1R) in vitro in a manner that competes with exendin-4 and induces GLP-1R-dependent cAMP signaling in cultured CHO-K1 cells expressing GLP-1R.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.